Physician profile
Drora Shevy
NPI 1639402704
$1,176.95
in general payments reported to CMS, 2019-2025
10 companies · $501 in 2025
The $501 reported for 2025 was more than what 84% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $124 · 2024: $552 · 2025: $501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,176.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Catalyst Pharmaceuticals, INC. | $351.08 | 2024-2025 | |
| Argenx US, INC. | $235.26 | 2023-2024 | Vyvgart Hytrulo |
| Ge Healthcare | $180.19 | 2024-2025 | |
| Tonix Medicines, INC. | $143.62 | 2024-2025 | Zembrace Symtouch |
| Alexion Pharmaceuticals, INC. | $104.77 | 2024 | Ultomiris |
| Sk Life Science, INC. | $62.14 | 2024-2025 | |
| Cycle Pharmaceuticals INC | $27.59 | 2025 | Tascenso Odt |
| Ani Pharmaceuticals, INC. | $26.33 | 2024 | Purified Cortrophin Gel |
| Emd Serono, INC. | $25.66 | 2025 | |
| Tanabe Pharma America, INC. | $20.31 | 2025 | Radicava |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Drora Shevy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.